Open AccessIntestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity
Author(s) -
Chung HeaJong,
Yu Jae G.,
Lee InAh,
Liu MingJie,
Shen YanFei,
Sharma Satya P.,
Jamal Mohammad A. H. M.,
Yoo JunHyun,
Kim HyeonJin,
Hong SeongTshool
Publication year - 2016
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12024
Subject(s) - obesity , food science , chemistry , microbiology and biotechnology , fatty acid , biochemistry , biology , endocrinology
Recent findings on the association of gut microbiota with various diseases, including obesity, prompted us to investigate the possibility of using a certain type of gut bacteria as a safe therapeutic for obesity. Lactobacillus mutants with enhanced capacity in absorption of free fatty acids ( FFA s) were isolated to show reduced absorption of FFA s by the administered host, attributing to inhibition of body weight gain and body fat accumulation as well as amelioration of blood profiles. Consequently, high throughput screening of natural FFA s‐absorbing intestinal microbes led to the isolation of Lactobacillus reuteri JBD 30 l. The administration of Lactobacillus JBD 30l lowered the concentration of FFA s in the gut fluid content of small intestine, thus reducing intestinal absorption of FFA s whereas promoting fecal excretion of FFA s. Animal data also confirmed that the efficacy of Lactobacillus JBD 30l on body weight similar to that of orlistat, an FDA ‐approved pharmaceutical for long‐term use to treat obesity. In a subsequent random, double‐blind, placebo‐controlled clinical trial ( KCT 0000452 at Clinical Research Information Service of Korea), there was a statistically significant difference in the percentage change in body weight between the Lactobacillus JBD 301 and the placebo group ( P = 0.026) as well as in the BMI ( P = 0.036) from the 0‐week assessment to the 12‐week assessment. Our results show that FFA ‐absorbing Lactobacillus JBD 301 effectively reduces dietary fat absorption, providing an ideal treatment for obesity with inherent safety.